<DOC>
	<DOCNO>NCT00076999</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability tipranavir ( TPV ) oral formulation soft gelatin capsule together low-dose ritonavir HIV-infected child adolescent , provide information concern pharmacokinetic characteristic tipranavir ritonavir age group , determine relative bioavailability TPV liquid formulation TPV capsule formulation adolescent switch liquid capsule . The secondary objective study determination dose topranavir ritonavir ( TPV/r ) child adolescents 2 18 year age require adult equivalent systemic exposure TPV/r 500 mg / 200 mg .</brief_summary>
	<brief_title>Pharmacokinetics Safety Study Tipranavir Combination With Low Dose Ritonavir Human Immunodeficiency Virus ( HIV ) -Infected Children</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>Inclusion criterion : 1 . Males females 2 18 year age . 2 . A confirmed diagnosis HIV1 infection define two positive assay two different sample take least two week apart . The two result may combination follow : HIV ribonucleic acid ( RNA ) detect reverse transcriptase ( RT ) polymerase chain reaction ( PCR ) HIV proviral deoxyribonucleic acid ( DNA ) detect PCR HIV culture p24 antigen detection Licensed HIV enzymelinked immunosorbent assay ( ELISA ) confirmatory Western blot 3 . Viral load &gt; 1500 RNA copies/mL . 4 . Acceptable screen laboratory value indicative adequate baseline organ function . Laboratory value consider acceptable severity high Grade 1 test define Division Acquired Immunodeficiency Syndrome ( DAIDS ) Table Grading Severity Pediatric Adverse Experiences ( &gt; 3 month age ) follow exception : Grade 2 gammaglutamyl transferase Grade 2 cholesterol Grade 2 triglyceride 5 . Signed informed consent prior study participation patient legal guardian . Active assent must give patient child and/or adolescent capable understanding provide study information ( apply child intellectual age 7 year great ) 6 . In opinion investigator , ability take medication comply requirement protocol . Exclusion criterion : 1 . Female patient childbearing potential : positive serum pregnancy test screen breast feeding plan become pregnant willing use two method contraception include least one barrier method ( e.g . latex condom plus spermicidal jelly/foam ) 2 . Active hepatitis B C disease define hepatitis B surface antigen ( HBsAg ) positivity hepatitis C ( HCV ) antibody RNA positivity aspartate aminotransferase ( AST ) / alanine aminotransferase ( ALT ) &gt; Grade 2 . 3 . Life expectancy &lt; 12 month . 4 . Patients unwilling abstain ingesting contraindicate medication substance may significantly affect plasma level study medication , notably : Grapefruit juice Seville oranges Herbal preparation contain St. John 's Wort milk thistle Garlic supplement 5 . Active substance abuse . 6 . Use investigational medication vaccine within 28 day study entry trial . Some expand access antiretroviral medication may acceptable , must approve sponsor . 7 . Requirement therapy malignancy immunomodulatory drug ( e.g . interferon , cyclosporine , hydroxyurea , interleukin2 ) within 28 day study entry . Replacement intravenous gamma globulin treatment acceptable . 8 . Any active opportunistic infection within 28 day study entry clinically significant finding may compromise outcome study . 9 . Patients malabsorption , severe chronic diarrhea vomit ( two episode moderate severe intensity , attribute medication therapy last four day ) within 28 day study . 10 . Evidence symptom encephalopathy developmental delay would reduce compliance .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>